Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-07-19 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 117.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities admitted on the basis of commitments.' It contains detailed financial data including consolidated cash flow statements for the current quarter and year to date, payments to directors, non-cash financing and investing activities, and financing facilities available. The presence of actual financial statements and substantive financial data for a quarter indicates this is a comprehensive interim or quarterly financial report. The document length is 15,000 characters, which is substantial and consistent with a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). FY 2011
2011-07-19 English
June 2011 Quarterly Report to Shareholders 8 pages 2.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report to Shareholders' and covers the period April to June 2011, indicating it is a quarterly report. It contains detailed business updates, product development progress, clinical trial results, regulatory status updates, and future plans. The content includes substantive financial and operational information relevant to a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a presentation, nor is it a transcript or a regulatory filing of a different nature. The length (15,000 characters) and depth of content confirm it is a comprehensive interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2011
2011-07-19 English
Quarterly Investor Conference Call 1 page 25.6KB
Call Transcript Classification · 90% confidence The document is a media release announcing an upcoming quarterly investor conference call and the release of the June 2011 Quarterly Report. It provides details about the teleconference timing, access numbers, and where to find the recording. The document itself does not contain the quarterly report or substantive financial data, but rather announces the event and report release. Given the short length (1165 characters) and the nature of the content as an announcement, it fits the category of a Call Transcript announcement or an Investor Presentation announcement. However, since it specifically announces a conference call with Q&A, the best fit is Call Transcript (CT). Confidence is high because the document clearly states it is about the conference call and the quarterly report release, but does not contain the report itself or the transcript yet.
2011-07-18 English
Bronchitol Resubmitted to Australian PBAC 2 pages 91.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 12 July 2011 from Pharmaxis Ltd announcing the resubmission of their drug Bronchitol to the Australian Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement consideration. It discusses regulatory and reimbursement processes, clinical trial results, and company strategy regarding the drug's listing on the Pharmaceutical Benefits Scheme (PBS). There are no financial statements, earnings data, or detailed financial analysis present. The document is a public announcement about a regulatory and reimbursement update rather than a financial report, management discussion, or investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about a pharmaceutical product's reimbursement status. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2011-07-11 English
Re-examination of Bronchitol Marketing Application Requested 2 pages 94.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 05 July 2011 from Pharmaxis Ltd announcing a formal request for re-examination of the European Bronchitol marketing application by the Committee for Medicinal Products for Human Use (CHMP). It discusses regulatory procedures, clinical trial results, and the company's expectations regarding the re-examination process. The document is a public announcement of a regulatory event and does not contain financial statements, detailed financial performance data, or management discussion of financial results. It is not a report, audit, or earnings release. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a marketing application re-examination and does not fit other more specific categories such as Capital/Financing Update or Legal Proceedings Report. The document length (7263 characters) and content confirm it is a full announcement rather than a brief report publication notice.
2011-07-04 English
Updated Investor Presentation 31 pages 2.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about a pharmaceutical product (Bronchitol) for respiratory diseases, including clinical trial data, background information, mode of action, and trial demographics. It contains extensive scientific and clinical information, figures, and tables. There is no indication that this is an official financial report, audit, regulatory filing, or announcement. The content is educational and strategic, aimed at investors or stakeholders to explain the product and its clinical progress. This matches the characteristics of an Investor Presentation (IP). The document length is substantial (15,000 characters), and it is not a brief announcement or certification. Therefore, the best classification is Investor Presentation (IP).
2011-06-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.